AUTL
NASDAQ
GB
Autolus Therapeutics plc - American Depositary Shares
$1.41
▲ +$0.03
(+2.17%)
Vol 1.0M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$524.3M
ROE
-63.8%
Margin
-439.7%
D/E
97.70
Beta
2.07
52W
$1–$3
Wall Street Consensus
18 analysts · Apr 20266
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
94.4%
Buy Rating
Price Chart
Similar Stocks
About Autolus Therapeutics plc - American Depositary Shares
Autolus Therapeutics (AUTL) — біотехнологічна компанія, що розробляє програмовані T-клітинні терапії для лікування раку. Компанія зосереджена на розробці CAR T-клітинних терапій наступного покоління, які мають покращену ефективність та безпеку. Autolus займає нішеву позицію на ринку, вирізняючись інноваційним підходом до програмування T-клітин та зосередженістю на гематологічних злоякісних пухлинах.
Earnings
Beat rate: 40.0%
Next Report
May 06, 2026
EPS Estimate: $-0.25
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.25 | — | — |
| Dec 2025 | $-0.27 | $-0.34 | $-0.07 |
| Sep 2025 | $-0.23 | $-0.30 | $-0.07 |
| Jun 2025 | $-0.24 | $-0.18 | +$0.06 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -56.2% | -56.2% | -56.2% | -56.2% | -63.8% | -63.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -229.0% | -486.7% | -486.7% | -486.7% | -439.7% | -439.7% |
| Gross Margin | -16.8% | — | — | — | -61.2% | -61.2% |
| D/E Ratio | 70.61 | 70.61 | 70.61 | 70.61 | 97.70 | 97.70 |
| Current Ratio | 8.43 | 8.43 | 8.43 | 8.43 | 6.19 | 6.19 |
Key Ratios
ROA (TTM)
-30.9%
P/S (TTM)
10.25
P/B
1.5
EPS (TTM)
$-0.84
CF/Share
$-0.97
Rev Growth 3Y
+63.2%
52W High
$2.80
52W Low
$1.11
$1.11
52-Week Range
$2.80
How does AUTL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AUTL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
10.3
▼
20%
below
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.5
▼
41%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AUTL profitability vs Biotechnology peers
ROE
-63.8%
▲
5%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-439.7%
▼
53%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
-61.2%
▼
178%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-30.9%
▲
34%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
AUTL financial health vs Biotechnology peers
D/E ratio
97.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
6.2
▲
40%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.1
▲
113%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
AUTL fundamentals radar
AUTL
Peer median
Industry
AUTL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio